News from Novo Nordisk A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Novo Nordisk

06 Nov, 2017, 08:45 GMT Switching to Tresiba® is Highly Cost-effective and Cost-saving in a Real-world Setting

Poster Presentation PDB27 A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and...


31 Oct, 2017, 12:00 GMT New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care

Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with...


29 Sep, 2017, 07:00 BST IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of...


15 Sep, 2017, 08:31 BST Tresiba® Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death

Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2...


13 Sep, 2017, 15:31 BST Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors...


12 Sep, 2017, 11:59 BST More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments

Poster # 820 A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a...


12 Sep, 2017, 11:59 BST Fiasp® Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Long-term

Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar...


28 Aug, 2017, 13:00 BST Victoza® Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular...


03 Jul, 2017, 08:00 BST Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Congress

Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis...


13 Jun, 2017, 02:30 BST New LEADER Analysis Shows Victoza® Reduces Cardiovascular Risk in People With Type 2 Diabetes Regardless of Severe Hypoglycaemia Events

Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in...


12 Jun, 2017, 22:15 BST Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in Rates of Severe Hypoglycaemia Compared to Insulin Glargine U100 in the DEVOTE Trial

Symposium: 3-CT-SY22 Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target,...


10 Jun, 2017, 18:00 BST Switching to Tresiba® Provides Significant Reductions in Blood Glucose and Lower Rates of Hypoglycaemia in a Real-world Setting

Poster Presentations #999-P, #1010-P, #1014-P Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented today at the...


17 May, 2017, 15:30 BST Early Response to Saxenda® Resulted in Weight Maintenance and Additional Weight Loss Over 56 Weeks

Abstract# RS3:3 Today, results from a post hoc analysis of data from the SCALE Maintenance trial were presented at the 24th European Congress on...


02 Apr, 2017, 18:00 BST Once-weekly Semaglutide Demonstrated Consistent Blood Glucose Reductions and Weight Loss Regardless of Background Oral Antidiabetic Treatment

Abstract #620 Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight...


27 Mar, 2017, 08:00 BST Fiasp®▼, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults

Canada first country to launch Fiasp® This material is intended for global medical media only. For journalistic assessment and preparation...


01 Feb, 2017, 07:00 GMT Flexible Storage Options can Impact Daily Use of FVIII Treatments in People with Haemophilia A

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster #P024 Patient...


03 Dec, 2016, 17:00 GMT NovoSeven® Resolved 96.5% of Bleeds When Initiated Within One Hour After Bleed Onset in People With Haemophilia A or B With Inhibitors

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today...


02 Dec, 2016, 08:00 GMT Xultophy®▼ (IDegLira) Demonstrates Similar Glucose Control With Reduced Risk of Hypoglycaemia and a Superior Weight Profile Compared to Basal-Bolus Therapy

This material is intended for UK medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today...


02 Dec, 2016, 08:00 GMT Xultophy® Demonstrates Similar Glucose Control with Reduced Risk of Hypoglycaemia and a Superior Weight Profile Compared to Basal-Bolus Therapy

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today...


14 Nov, 2016, 07:00 GMT Novo Nordisk forlænger og udvider program for børn med type 1-diabetes i udviklingslande

Novo Nordisk har besluttet at forlænge sit Changing Diabetes® in Children-program med fire år - et program, som giver børn med type 1-diabetes i...


14 Nov, 2016, 07:00 GMT Novo Nordisk prolonge son programme afin de prendre en charge jusqu'à 20 000 enfants atteints de diabète dans les pays en voie de développement

Aujourd'hui, Novo Nordisk a annoncé une prolongation de quatre ans de son programme intitulé Changing Diabetes® in Children. Spécialement conçu...


14 Nov, 2016, 07:00 GMT Novo Nordisk erweitert sein Hilfsprogramm auf 20.000 Kinder mit Diabetes in Entwicklungsländern

Novo Nordisk gab heute eine Verlängerung seines Engagements "Changing Diabetes® in Children" um vier Jahre bekannt. Das Hilfsprogramm bietet...


14 Nov, 2016, 07:00 GMT Novo Nordisk amplía su programa humanitario para llegar a 20.000 niños con diabetes en los países en desarrollo

Novo Nordisk ha anunciado una ampliación de cuatro años en su programa Changing Diabetes® in Children que proporciona acceso al cuidado de la...


14 Nov, 2016, 07:00 GMT Novo Nordisk Expands Programme to Reach 20,000 Children with Diabetes in Developing Countries

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and...


12 Nov, 2016, 08:00 GMT Tresiba® Demonstrated Lower Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Compared With Insulin Glargine U300

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a...